Revenue, 2025

USD 3.9 Billion

Forecast, 2035

USD 16.91 Billion

CAGR, 2026-2035

15.8%

Report Coverage

Global

Small Interfering RNA (siRNA) Market Trends for 2026

The global small interfering RNA (siRNA) market size was estimated at USD 3.9 billion in 2025 and is predicted to increase from USD 4.52 billion in 2026 to approximately USD 16.91 billion by 2035, expanding at a CAGR of 15.8% from 2026 to 2035. The Market is expanding, driven by growing interest in gene-silencing therapies and advancements in RNA-based drug development. Rising cases of chronic and genetic diseases, along with improving delivery technologies, are accelerating adoption across oncology and rare disease treatments.

Key Takeaways

• Small interfering RNA (siRNA) sector pushed the market to USD 4.52 billion by 2026.
• Long-term projections show USD 16.91 billion valuation by 2035.
• Growth is expected at a steady CAGR of 15.8% in between 2026 to 2035.
• North America dominated the small interfering RNA (siRNA) market with a share of 42% in 2025.
• Asia Pacific captured 17% of the market in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period.
• By type, the synthetic siRNA segment dominated the market with a revenue share of 58% in 2025.
• By type, the dicer-substrate siRNA (DsiRNA) segment held a 17% share in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period.
• By delivery method, the lipid-based delivery segment held a dominant share of 46% in 2025.
• By delivery methods, the conjugate-based delivery segment held the second-largest share of 21% of the market in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period.
• By application, the therapeutics segment led the market with a share of 52% in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period.
• By end user, the pharmaceutical & biotechnology segment held a dominant share of 49% in 2025 and is expected to grow at the fastest CAGR in the small interfering RNA (siRNA) market during the forecast period.
• By route of administration, the intravenous segment held a dominant share of 38% in 2025.
• By route of administration, the subcutaneous segment held the second-largest share of 29% of the market in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period.

Gene-Silencing Revolution Driving siRNA Market Growth

Small interfering RNA (siRNA) is a class of short, double-stranded RNA molecules that silence specific genes by degrading targeted messenger RNA (miRNA). The small interfering RNA (siRNA) market is expanding due to increasing demand for targeted therapies that can precisely silence disease-causing genes. Growth is supported by the rising prevalence of chronic and genetic disorders, ongoing advancements in RNA delivery technologies, and strong investment in biotechnology research. Additionally, a growing pipeline of RNA-based drugs and expanding clinical applications in oncology and rare diseases are accelerating market adoption.

How Can AI Affect the Small Interfering RNA (siRNA) Market?

AI is transforming the market by accelerating target identification, optimizing sequence design, and predicting off-target effects with greater accuracy. It helps improve delivery systems and reduces development time and costs. Additionally, AI-driven analytics enhance clinical trial success rates and enable personalized therapies, supporting faster commercialization and broader adoption of siRNA-based treatments across multiple disease areas.

Trend and Future Outlook of the Small Interfering RNA (siRNA) Market?

• Expansion of Therapeutic Applications: The siRNA is moving beyond rare genetic disorders into broader areas like oncology, cardiovascular, and infectious diseases. This diversification is increasing commercial potential and encouraging more clinical trials and regulatory approvals globally.
• Advancements in Delivery Technologies: Improved delivery systems, such as lipid nanoparticles and conjugate-based platforms, are enhancing the stability and targeted delivery of siRNA therapies. These innovations are addressing past limitations, making treatments more effective and safer for widespread clinical use.
• Growing Industry Investment and Partnerships: Rising investments from pharmaceutical companies and strategic collaborations with biotech firms are accelerating research and development. These partnerships are strengthening pipelines, speeding up drug commercialization, and shaping a robust future outlook for the siRNA market.

Key Indicators and Highlights

Segmental Insights

By Type

The Synthetic siRNA Segment Dominated the Market in 2025

The synthetic siRNA segment dominated the small interfering RNA (siRNA) market with a revenue share of 58% in 2025 due to its high stability, precision gene-targeting ability, and scalable manufacturing compared to natural RNA forms. It offers improved safety, consistent quality, and easier chemical modification, enhancing therapeutic efficiency. Strong adoption in clinical pipelines for rare genetic, cardiovascular, and oncology diseases, along with advancements in delivery systems like lipid nanoparticles, further strengthened its leading market position.

The short hairpin RNA (shRNA) segment held the second-largest share of 25% of the market in 2025 due to its ability to provide sustained and long-lasting gene silencing through continuous intracellular expression. It is widely used in functional genomics, cancer research, and genetic disorders studies. Cost-effective production, efficient viral vector delivery systems, and strong research applications in gene knockdown experiments further drive its adoption, supporting its steady growth in the siRNA market.

The dicer-substrate siRNA (DsiRNA) segment held a 17% share in 2025 and is expected to grow at the fastest CAGR in the small interfering RNA (siRNA) market during the forecast period due to its higher gene-silencing efficiency and improved potency compared to traditional siRNA molecules. It requires lower doses for effective results, reducing toxicity risks and improving safety profiles. Increasing adoption in cancer and genetic disorders research, along with advancements in RNA delivery technologies and expanding clinical pipeline applications, further support its rapid market growth.

By Delivery Method Insights

The Lipid-based Delivery Segment Led the Market in 2025 with the Largest Share

The lipid-based delivery segment held a dominant share of 46% in 2025 due to its high efficiency in protecting RNA molecules and enabling targeted cellular delivery. Lipid nanoparticles enhance stability, reduce degradation, and improve gene-silencing effectiveness in vivo. Their proven success in FDA-approved therapies and strong application in liver, cardiovascular, and strong application in liver, cardiovascular, and genetic disorders further drive widespread adoption, making them the preferred delivery system for siRNA therapeutics.

The conjugate-based delivery segment held the second-largest share of 21% of the small interfering RNA (siRNA) market in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period due to its high specificity and ability to target particular tissues, especially the liver, without requiring complex carriers. Technologies like GaINAc conjugation improve cellular uptake stability and reduce off-target effects. Its convenience, lower immunogenicity, and successful use in FDA-approved therapies make it a strong alternative to lipid-based delivery systems in clinical applications.

The polymer-based delivery segment held 18% of the small interfering RNA (siRNA) market share in 2025 due to its ability to provide stable, controlled, and sustained release of RNA molecules. Polymers enhance protection against enzymatic degradation and improve cellular uptake while allowing flexible chemical modification. Increasing research in biodegradable and biocompatible polymers, along with expanding applications in oncology and genetic disorders, is driving adoption as an emerging alternative delivery platform for siRNA therapies.

The viral delivery systems segment held 9% of the small interfering RNA (siRNA) market share in 2025 due to its high efficiency in delivering genetic material directly into target cells. Viral vectors enable strong and long-lasting gene silencing, making them suitable for complex diseases like cancer and genetic disorders. Increasing use in research applications, improved vector engineering, and advancements in safety and specificity are further driving the adoption of viral-based siRNA delivery approaches.

By Application Insights

The Therapeutics Segment Led the Market in 2025 with the Largest Share

The therapeutics segment led the market with a share of 52% in 2025 and is expected to grow at the fastest CAGR in the small interfering RNA (siRNA) market during the forecast period due to the increasing adoption of RNA interference technology for treating genetic, rare, and chronic diseases. Growing FDA approvals of siRNA-based drugs, rising prevalence of conditions like cardiovascular disorders, cancers, and metabolic diseases, and strong clinical pipeline development are drivers. Additionally, advancements in targeted delivery systems and expanding use in precision medicine further strengthen its dominance in clinical applications.

The research & functional genomics segment held 28% of the small interfering RNA (siRNA) market share in 2025 due to its widespread use in gene silencing studies, target validation, and understanding gene function. Increasing adoption in drug discovery programs, rising demand for advanced molecular biology tools, and expanding academic and pharmaceutical research activities are key drivers. SiRNA’s ability to selectively knock down genes makes it highly valuable in functional genomics and biomedical research applications.

The drug discovery & development segment held 20% of the small interfering RNA (siRNA) market share in 2025 due to increasing use of RNA interference technology for identifying and validating new therapeutic targets. Growing investment in precision medicine, rising demand for faster and more efficient drug development processes, and advancements in delivery systems are key drivers. Additionally, expanding clinical pipelines for genetic, cancer, and rare diseases further strengthened siRNA’s role in modern drug development

By End User

The Pharmaceutical & biotechnology Segment Led the Market in 2025 with the Largest Share

The pharmaceutical & biotechnology segment held a dominant share of 49% in 2025 and is expected to grow at the fastest CAGR in the small interfering RNA (siRNA) market during the forecast period due to strong investment in RNA-based drug development and large-scale clinical research capabilities. These companies drive innovation through robust pipelines targeting genetic, cardiovascular, and oncology diseases. Advanced infrastructure, expertise in biologics manufacturing, and strategic collaborations further support their dominance, enabling faster commercialization and wider adoption of siRNA therapeutics across global healthcare markets.

The academic & research institutes segment held 27% of the small interfering RNA (siRNA) market share in 2025 due to increasing focus on gene function studies and early-stage drug discovery. Rising government funding, expanding genomics research programs, and growing collaborations with pharmaceutical companies are key drivers. Additionally, widespread use of siRNA in functional genomics and molecular biology research is accelerating demand across universities and research organizations.

The contract research organizations segment held 15% of the small interfering RNA (siRNA) market share in 2025 due to increasing outsourcing of research and clinical trial activities by pharmaceutical and biotechnology companies. CROs offer cost-effective, specialized expertise and faster study execution, supporting efficient drug development. Rising demand for RNA-based therapies, growing clinical pipelines, and the need to reduce development timelines are driving greater reliance on CRO services in the siRNA space.

The hospitals & clinics segment held 9% of the small interfering RNA (siRNA) market share in 2025 due to increasing availability of approved RNA-based therapies and rising patient demand for advanced targeted treatments. Growing diagnosis of genetic and chronic diseases is driving treatment uptake in clinical settings. Additionally, improvements in healthcare infrastructure, physician awareness, and integration of precision medicine approaches are supporting wider adoption of siRNA therapies across hospitals and specialty clinics.

By Route of Administration Insights

The Intravenous Segment Led the Market in 2025 with the Largest Share

The intravenous segment held a dominant share of 38% in 2025 due to its ability to deliver therapies directly into the bloodstream, ensuring rapid distribution and high bioavailability. It is widely used for approved siRNA drugs, especially for liver-targeted treatments, where precise dosing and controlled administration are critical. Compatibility, clinical preference, hospital-based administration, and compatibility with lipid nanoparticle delivery systems further support its leading position in the market.

The subcutaneous segment held the second-largest share of 29% of the market in 2025 and is expected to grow at the fastest CAGR in the small interfering RNA (siRNA) market during the forecast period due to its convenience, allowing self-administration and improved patient compliance compared to intravenous methods. It offers sustained drug release and is widely used in therapies targeting chronic conditions like hypercholesterolemia. Growing preference for less invasive treatment options, along with successful use in approved siRNA drugs, is driving its strong adoption in clinical practice.

The intrathecal segment held 12% of the small interfering RNA (siRNA) market share in 2025 due to its ability to deliver therapies directly into the central nervous system, bypassing the blood-brain barrier. This approach enhances treatment effectiveness for neurological and genetic disorders. Increasing research in CNS-targeted therapies, along with advancements in delivery techniques, is driving their adoption in specialized clinical applications.

The intranasal segment held 11% of the small interfering RNA (siRNA) market share in 2025 due to its non-invasive nature and ability to deliver therapies directly to the brain via the nasal route, bypassing the blood-brain barrier. This enhances the potential treatment of neurological disorders. Increasing research focus, ease of administration, and improved patient compliance are further supporting its growing adoption.

Regional Insights

North America Leads the Small Interfering RNA (siRNA) Market

North America dominated the small interfering RNA (siRNA) market with a share of 42% in 2025 due to its well-established biotechnology and pharmaceutical industry, supported by high research and development investments and advanced healthcare infrastructure. The region benefits from early adoption of innovation, RNA-based therapies, strong pressure from key market players, and a robust clinical trial landscape. Favorable regulatory frameworks and increasing focus on precision medicine further accelerate the development and commercialization of siRNA treatments.

U.S. Market Trends

The U.S. leads the small interfering RNA (siRNA) market due to its strong biotech ecosystems, high R&D funding, and presence of major pharmaceutical companies. Advanced clinical trial infrastructure, rapid adoption of precision medicine, and supportive regulatory pathways further accelerate innovation. Additionally, growing investments in gene-silencing therapies and a robust pipeline of siRNA candidates are strengthening the country’s market leadership position.

Rapid Growth Hub Fueling siRNA Expansion in the Asia Pacific

Asia Pacific held 17% share of the market in 2025 and is expected to grow at the fastest CAGR in the small interfering RNA (siRNA) market due to rising healthcare investments, increasing prevalence of genetic and chronic diseases, and expanding biotechnology research capabilities. Growing clinical trials activity, improving regulatory support, and cost-effective drug development environments in countries like China, India, and Japan are further attracting global pharmaceutical companies, accelerating regional market growth significantly during the forecast period.

India Emerging as a High-Growth siRNA Market Hub

India is projected to grow at the fastest CAGR in the small interfering RNA (siRNA) market due to the rapidly expanding biotechnology sector, increasing prevalence of genetic and chronic diseases, and rising government support for life science research. Growing clinical trial activities, availability for skilled scientific talent, and cost-effective R&D infrastructure are attracting global pharmaceutical investments, accelerating the adoption of advanced RNA-based therapies during the forecast period.

Supply Chain Analysis

Clinical Trails

• Clinical trials in small interfering RNA (siRNA) are reshaping precision medicine by enabling gene silencing for diseases that were previously hard to treat, with several FDA-approved therapies already in use. Current research is focused on improving delivery beyond the liver and expanding applications in cancer, cardiovascular, and genetic disorders using lipid nanoparticles and GalNAc conjugation.
• Key players: Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals.

Regulatory Approvals

• Small interfering RNA (siRNA) therapies are now an established drug class, with multiple FDA approvals since 2018 for rare genetic disorders and cardiovascular conditions like high cholesterol. Approved treatments include Patisiran, Givosiran, Lumasiran, Inclisiran, Vutrisiran, and Nedosiran, marking strong clinical validation of RNA interference technology.
• Key players: Alnylam Pharmaceuticals, Novartis, Arrowhead Pharmaceuticals.

Patient Support and Services

• Patient support in small interfering RNA (siRNA) therapies is designed to help patients manage complex and high-cost treatments for rare and chronic diseases such as hATTR amyloidosis and hypercholesterolemia. Support programs typically include financial assistance, specialized nursing care, long-term disease monitoring, and premedication to reduce infusion reactions. Regular follow-ups, including vitamin A level monitoring for therapies like patisiran, are also provided.
• Key players involved include Alnylam Pharmaceuticals, Pfizer, and Novartis.

Top Vendors in the Small Interfering RNA (siRNA) Market & Their Offerings

SWOT Analysis

Strengths

• Highly targeted gene-silencing mechanism enables precise treatment of genetic and chronic diseases.
• A growing number of FDA-approved siRNA drugs validates clinical and commercial potential.
• Strong R&D pipeline supported by leading biotech and pharmaceutical companies globally.

Weaknesses

• High development and manufacturing costs limit accessibility and scalability.
• Delivery challenges, especially beyond liver targeting, still restrict broader applications.
• Risk of off-target effects and immune responses affects safety perception.

Opportunities

• Expanding applications in oncology, cardiovascular, and rare diseases.
• Advancements in delivery technologies like lipid nanoparticles and GalNAc conjugation.
• Increasing global investment and partnerships in RNA-based therapeutics.

Threats

• Intense competition from other gene-editing technologies like CRISPR.
• Strict regulatory pathways are delaying approvals in some regions.
• Patent expirations and pricing pressure from biosimilar and alternative therapies.

What are the Recent Developments in the Small Interfering RNA (siRNA) Market?

• In January 2026, Ribo Life Science, a key player in siRNA therapeutics, successfully went public through an IPO on the Hong Kong Stock Exchange. The company aims to utilize the raised funds to advance its RNA-based drug pipeline into clinical development, targeting cardiovascular, kidney, liver, and metabolic diseases.
• In September 2025, Mabwell Bioscience and Aditum Bio formed a new company, Kalexo Bio, to advance the development of a novel siRNA therapy. Their lead candidate, 2MW7141, demonstrated strong preclinical results in lowering target gene expression linked to lipid control and reducing the risk of atherosclerotic cardiovascular disease in dyslipidemia patients. Both companies plan to jointly progress 2MW7141 into clinical trials.

Segments Covered in the Report

By Type

• Synthetic siRNA
  • Chemically Modified siRNA
  • Unmodified siRNA
• Dicer-substrate siRNA (DsiRNA)
• Short Hairpin RNA (shRNA0
  • Viral Vector-based shRNA
  • Non-viral Vector-based shRNA

By Delivery Method

• Lipid-based Delivery
  • Lipid Nanoparticles (LNPs)
  • Liposomes
• Polymer-based Delivery
  • Polymeric Nanoparticles
  • Dendrimers
• Conjugate-based Delivery
  • GaiNAc-siRNA Conjugates
  • Peptide Conjugates
• Viral delivery systems
• Other Delivery Methods

By Application

• Therapeutics
  • Oncology
  • Rare Genetic Disorders
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
• Research & Functional Genomics
• Drug Discovery Development

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organization (CROs)
• Hospitals & Clinics

By Route of Administration

• Intravenous
• Subcutaneous
• Intrathecal
• Intranasal
• Others

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA